AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PRLD · NASDAQ · Biotechnology

Prelude Therapeutics

Develops small-molecule oncology programs centered on JAK2V617F inhibition and KAT6A degradation.

$5.52

After-hours close+0.06 (+1.04%)

At close$5.47(−13.80%)

Something off on this page? Send us feedback.

Profile

Prelude Therapeutics IncorporatedPRLDHealth Care

Develops precision-oncology drug candidates through a discovery engine spanning cancer biology, medicinal chemistry, and clinical development. Its pre-commercial pipeline centers on PRT12396, a mutant-selective JAK2V617F inhibitor, and PRT13722, an oral KAT6A degrader.

Develops precision-cancer medicines by combining cancer biology, medicinal chemistry, and clinical-development capabilities. The clinical-stage, pre-commercial pipeline centers on PRT12396, a mutant-selective JAK2V617F inhibitor in Phase 1 for polycythemia vera and myelofibrosis, alongside PRT13722, an oral KAT6A degrader at the IND stage.

The company also maintains precision degrader-antibody conjugate discovery. It operates as a single segment with no product sales, so its work depends on clinical progress, regulatory clearance, and financing. Prelude retains ownership and development responsibility for the JAK2 program while Incyte holds an option to acquire it during the option period.

Company facts

CEOKrishna Vaddi, Ph.D.

ListedSep 25, 2020

ExchangeNASDAQ

HeadquartersWilmington, DE

CountryUnited States

Employees79

CIK0001678660

ISINUS74065P1012

Key statistics

Market cap$311.4M

EPS (ttm)−$0.7900

P/E (ttm)−6.92

ROE-75.4%

P/B4.02

P/S13.89

Dividend yield—

Beta1.96vs XLV 0.84

Year to date +100% · Average volume (30d) 485.8K

Analysts

Price target, next 12 months$8.00+46.3%Median of 8 analysts · vs the Aug 28 close

ConsensusBuy5 of 8 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $5.47

High$8.00+46.3%

Median$8.00+46.3%

Low$8.00+46.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Apr 27, 2026	H.C. Wainwright	Target			$5	$8
Sep 19, 2024	HC Wainwright & Co.	Upgrade	Neutral	Buy

Earnings

EPS

Estimate−$0.16

ReportedDue Nov 11, 2026

Revenue

Estimate$35.3M

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 11, 2026Q2 FY26	−$0.20	−$0.14	+28.8%	$5.7M	$5.7M	0.0%	+10.14%
May 12, 2026Q1 FY26	−$0.27	−$0.13	+51.9%	$4.6M	$4.6M	0.0%	+0.43%
Mar 10, 2026Q4 FY25	−$0.33	−$0.20	+39.4%	$20.5M	$5.6M	−72.7%	+5.83%
Nov 12, 2025Q3 FY25	−$0.35	−$0.26	+25.7%	$20.5M	$6.5M	−68.3%	+2.72%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$6.5M	$5.6M	$4.6M	$5.7M
Gross profit	$0	$0	$6.5M	$5.6M	$4.2M	$5.7M
Operating income	−$34.6M	−$32.2M	−$20.4M	−$17.3M	−$14.2M	−$15.5M
Net income	−$32.1M	−$31.2M	−$19.7M	−$16.5M	−$10.4M	−$13.9M
Diluted EPS	−$0.42	−$0.41	−$0.26	−$0.26	−$0.13	−$0.14
Gross margin	—	—	100.0%	100.0%	91.5%	100.0%
Operating margin	—	—	-314.1%	-307.6%	-309.5%	-270.9%

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $7.0M · FY25 $12.1M

Balance sheet, Jun 30, 2026Cash & short-term investments $151.8M · Total debt $17.7M · Total assets $189.4M · Shareholders' equity $133.7M

Dividends

No dividends on record.

Ownership

Institutions 39.20%30.77M sharesInsiders 5.01%3.94M sharesOther 55.79%43.79M shares

Shares outstanding 78.50M · Float 41.76M · 53.2% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Baker Bros. Advisors (GP) LLC	10.30M	15.50%	13D	Apr 22, 2026
Vaddi Krishna	6.75M	13.15%	13G	Feb 13, 2026
Ra Capital Management, L.P. · 10 percent owner	6.48M	8.25%	Form 4	Apr 28, 2026
Incyte Corp	4.37M	9.90%	13G	Nov 7, 2025
Kynam Capital Management, LP	1.59M	2.03%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Apr 21, 2026	Orbimed Advisors LLC	director, 10 percent owner:	+2,815,315	$4.44
Apr 21, 2026	David P. Bonita	director, 10 percent owner:	+2,815,315	$4.44
Apr 21, 2026	Baker Bros. Advisors LP	director, 10 percent owner:	+2,252,252	$0.0001